Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout

Lihua Duan, Jiao Luo, Qiang Fu, Ke Shang, Yingying Wei, Youlian Wang, Yan Li, and Jie Chen

1Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People’s Hospital, Nanchang, China
2Department of Rheumatology and Clinical Immunology, University of Lübeck, Germany
3Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, China
4Department of Scientific Research and Education, Jiangxi Provincial People’s Hospital, Nanchang, China

Correspondence should be addressed to Youlian Wang; wyl5639@sina.com, Yan Li; liy010203@163.com, and Jie Chen; jiechen86213@163.com

Received 21 March 2019; Accepted 7 May 2019; Published 13 June 2019

Gout is a common metabolic disease in humans, and it is due to persistently elevated levels of uric acid in the blood. At high levels, uric acid crystallizes and the crystals deposit in joints and surrounding tissues, resulting in an attack of gout. Interestingly, the gout attack can spontaneously resolve within a few days. However, the self-limited mechanism of gout remains elusive. It has been demonstrated that CD14 plays an important role in self-remission of gout. In this study, we found that the proportion of CD14-positive PBMCs was decreased in gout patients when compared with healthy controls and the serum sCD14 level was also considerably decreased in gout patients in comparison to healthy controls. In addition, sCD14 levels were positively correlated with CRP levels. Furthermore, the effect of MSU on the levels of CD14 in healthy volunteer’s PBMC was explored in in vitro experiment. The results showed that CD14 expression on macrophage and sCD14 levels in the culture supernatants were significantly decreased after MSU treatment. However, there was no significance in the levels of membrane CD14 and sCD14 in healthy volunteer’s PBMC stimulated by LPS. Taken together, these results suggest that CD14 might play an important role in self-remission of gout.

1. Introduction

Gout is a common metabolic disease in humans, which is caused by the purine metabolism disorder [1]. The pathological feature of gout is chronic deposition of monosodium urate (MSU) crystals in joints and surrounding tissues, which results from serum uric acid concentration rise above the physiological saturation [2] [3]. The deposition of MSU in joints and surrounding tissues activates the resident tissue macrophage, leading to an acute inflammatory response [4]. The activated macrophages produce abundant amounts of TNF-α, IL-1β, IL-6, IL-8, and chemotactic factors. Recent studies have demonstrated that IL-1β is the critical cytokine in the development of MSU-induced inflammation [5, 6]. However, IL-1β indirectly recruits a marked number of neutrophils into the joint cavity through promoting the production of adherence molecules of endothelial cells [7, 8]. This process is associated with the clinical manifestation of an acute gout attack. Interestingly, acute gout attack is an acute inflammatory disease characterized by self-limiting inflammation in response to the deposition of MSU crystals in the joints or tissues [9]. Until recently, the reason for the spontaneous rapid resolution of inflammation in gout was still unclear.

CD14, a GPI-anchored protein, is constitutively expressed on the surface of various cells, including monocytes, macrophages, polymorphonuclear neutrophils [10], B cells [11], and dendritic cells [12]. CD14 is the specific coreceptor for lipopolysaccharide (LPS) which is a compound of the outer cell wall of Gram-negative bacteria [13]. CD14 has two forms, membrane-bound (mCD14) and a circulating soluble (sCD14) [14, 15]. On the cell surface of monocyte, LPS
interacts with mCD14 and the LPS-binding protein (LBP) and forms a high-affinity trimolecular complex which result in the intracellular signaling pathway activation and lots of inflammatory cytokines, including IL-1β and IL-6 [16–18]. sCD14 is the form of CD14 without glycosylphosphatidylinositol tail and can be detected in serum [14, 19]. It was demonstrated that sCD14 is released from cellular membrane CD14 through the protease-dependent mechanism [14, 20]. Actually, sCD14 also play an important role in LPS-mediated activation of cells that lack membrane-bound CD14 such as endothelial and epithelial vascular [21, 22].

Previous studies have shown that MSU crystals activate macrophage in a manner that requires the canonical signaling pathway via TLR4 and TLR2. In addition, TLR2 and TLR4 mediate macrophage uptake of MSU crystals in vitro. Furthermore, the TLR signaling pathway recruits the intracellular adapter protein myeloid differentiation factor (MyD88), which also plays a critical role in the MSU uptake by macrophage in a manner that requires the canonical signaling pathway activation and lots of inflammatory mediators [21, 22]. As a pattern molecule, CD14 is also crucial for MSU crystal uptake, caspase-1 activation, and IL-1β production. A decreased uptake of MSU was observed in CD14 knockout mice [25]. However, the acute attack of gout is usually self-limited, and the reason for the spontaneous rapid resolution of MSU-induced inflammation was rather enigmatic. Some studies showed that a switch from proinflammatory to anti-inflammatory macrophages and increased production of anti-inflammatory mediators TGF-β and IL-10 have been discussed as potential factors responsible for the resolution of inflammation in gout [26].

Recently, neutrophil extracellular trap formation (NETosis) was also involved in the self-limited inflammation. It is highly potent to trap and cleave MSU-induced inflammatory cytokines within minutes [27]. In this study, we demonstrated that CD14 might play an important role in self-resolution of gout.

2. Materials and Methods

2.1. Patients’ Characteristics and Controls. 40 adult patients (2 females, aged 57.25 ± 19.62 years) with a diagnosis of gout based on the American College of Rheumatology/European League Against Rheumatism criteria [28] were consecutively enrolled in the study after providing informed consent. All patients were referred from the Department of Rheumatology and Clinical Immunology at the Jiangxi Provincial People’s Hospital and the First Affiliated Hospital of Xiamen University. The control group consisted of 31 healthy volunteers (3 females, aged 56.75 ± 12.36 years) that were enrolled after giving informed consent. Additional blood for PBMC isolation was harvested from 26 patients and 20 controls. Table 1 depicts the demographic and clinical characteristics of all patients and controls. All clinical manifestations and laboratory findings were recorded on the day of blood withdrawal.

2.2. Flow Cytometry Analysis. The peripheral blood of gout patients and healthy controls was collected in coagulant tubes. Peripheral blood mononuclear cells (PBMCs) were isolated by standard Ficoll-Hypaque density gradient centrifugation for 30 min. PBMC was stained by anti-human CD14 or CD68 (BioLegend).

2.3. ELISA. Four milliliters of blood was collected in sterile coagulant tubes and was then centrifuged at 3,500 rpm for 5 min at ambient temperature to obtain serum, which was immediately frozen and stored at -80°C until batch analysis. Concentrations of sCD14 were determined by ELISA kits (R&D) according to the manufacturer’s protocols.

2.4. Cell Culture. PBMCs of healthy volunteers were stimulated with 30 μg, 100 μg, and 300 μg/mL of MSU for 16 h. As a contrast, PBMCs from healthy volunteers were stimulated with 100 ng, 1 μg, and 10 μg/mL of LPS for 16 h. The cells and culture supernatants were harvested for flow cytometry and ELISA analysis, respectively.

2.5. Statistical Analysis. All data were analyzed using GraphPad Prism 5. Statistical significance was determined by unpaired Student’s t-test, Mann-Whitney U test, and Spearman’s correlation analysis which were used to calculate significance.

3. Results

3.1. Clinical Characteristics of Gout Patients. The clinical characteristics of gout patients (Table 1) were summarized for this study. 40 patients with gout and 31 healthy controls from Southern Chinese population were enrolled. The mean age for gout patients was 57.25 ± 15.62 years, and there were 38 males and 2 females. The mean ± SD of CRP, ESR, and UA was 75.21 ± 70.29 mg/L, 51.76 ± 29 mm/h, and 492.80 ± 148.3 μmol/L, respectively. Among these 40 patients, 35 patients (87.5%) had acute gout attack, 15 patients (37.5%) had tophi, 13 patients (32.5%) had gouty kidney damage, and 4 patients (10%) had fever. It was remarkable that 27 patients (67.5%) had hyperuricemia.

3.2. Decreased CD14 Expression in Gout Patients. To explore the role of CD14 in the spontaneous remission of gout, PBMC and serum were harvested to analyze the membrane and soluble CD14 in the gout patients and healthy controls by flow cytometry and ELISA. In comparison with healthy controls, the expression of mCD14 on PBMC was significantly lower in gout patients (Figure 1(a)). Consistently, sCD14 in serum from gout patients was also markedly lower than that from healthy controls (Figure 1(b)).

3.3. Correlation between sCD14 in Serum and Laboratory Parameters in Gout Patients. C-reactive protein (CRP) is an acute phase and inflammatory marker for the disease activity index in patients with gout. To evaluate the role of CD14 in the development of acute gout, the relationship between sCD14 levels and inflammatory marker CRP in gout patients was analyzed. As shown in Figure 2(a), we found that the sCD14 levels were positively correlated with CRP levels (r = 0.48, p = 0.0026). However, no significantly negative correlation was observed between serum sCD14 and UA (r = -0.3126, p = 0.0495). In keeping with previous study, our result pinpointed that CD14 was also linked to
Table 1: Demographic data and clinical characteristics of subjects in the study.

|                          | Gout patients (n = 40) | Healthy controls (n = 31) |
|--------------------------|------------------------|---------------------------|
| Age (year, mean ± SD)    | 57.25 ± 15.62          | 56.75 ± 12.36             |
| Male sex (%)             | 95%                    | 92%                       |
| CRP (C-reactive protein) (mg/L, mean ± SD) | 75.21 ± 70.29         | —                         |
| UA (uric acid) (μmol/L, mean ± SD) | 492.80 ± 148.3   | —                         |
| ESR (erythrocyte sedimentation rate) (mm/h, mean ± SD) | 51.76 ± 29.00      | —                         |
| Acute phase (%)          | 87.5%                  | —                         |
| Hyperuricemia (%)        | 67.5%                  | —                         |
| Tophi (%)                | 37.5%                  | —                         |
| Gouty kidney damage (%)  | 32.5%                  | —                         |
| Fever (%)                | 10%                    | —                         |

Figure 1: The CD14 expression was decreased in gout patient. (a) The PBMCs from gout patients (n = 26) and healthy controls (HC) (n = 20) were harvested and stained with the anti-CD14 antibody and then subjected to flow cytometry to detect the mCD14 expression. The CD14-positive cells were gated for analysis. (b) The serum levels of sCD14 in gout patients (n = 40) and HC (n = 31) were detected by ELISA. The Mann-Whitney U test was conducted to evaluate the significant difference of patients and controls. Each symbol represents an individual sample; horizontal lines indicate median values.

Figure 2: The correlation of sCD14 with inflammatory marker CRP and uric acid in gout patients. The relationships between sCD14 levels and CRP and UA in gout patients were analyzed. (a) sCD14 was positively correlated with CRP in gout patients (r = 0.48, p = 0.0026). (b) sCD14 was negatively correlated with UA in gout patients (r = −0.3126, p = 0.0495). Spearman’s correlation analysis was used to evaluate significance.
the development of gout inflammation. In addition, it is worth noting that the decreased CD14 in the gout patients might be implicated in the process of resolution of inflammation in gout.

3.4. MSU Downregulates Membrane CD14 Expression on PBMCs. To further ascertain that the CD14 expression was downregulated by MSU stimulation, we harvested the PBMCs from healthy controls and treated them with different doses of MSU. Although low MSU concentration has no obvious effect on the mCD14 expression of PBMCs, a significantly reduced CD14 expression was observed in PBMCs stimulated with high MSU concentration (Figure 3(a)). Next, CD68, the specific marker of monocytes/macrophage, were labeled and subjected to flow cytometry to analyze the CD14 expression. In parallel with the above result, the CD14 expressions on CD68+ monocytes/macrophages were markedly reduced in PBMC with higher MSU concentration treatment (Figure 3(b)). However, LPS has no obvious effect on CD14 expression in PBMC and CD68+ monocytes/macrophages (Figures 3(c) and 3(d)).

3.5. MSU Reduces the Level of Soluble CD14. Next, we tested the level of sCD14 in the culture supernatant of PBMCs treated with different concentrations of MSU or LPS. Consistently, sCD14 levels on the PBMCs with PBS and 30 μg/mL MSU treatment were not reduced. However, a significantly decreased sCD14 production was observed in PBMCs treated with MSU (Figure 3(d)).
The unpaired Student supernatants were harvested and subjected to ELISA analysis. Data from three independent experiments are presented as mean ± SD. mCD14 expression was significantly decreased in PBMCs stimulated with MSU (30 μg/mL, 100 μg/mL, and 300 μg/mL) compared to those from healthy control subjects. In addition, the reduced CD14 production in MSU-induced inflammatory resolution might contribute to spontaneous rapid resolution of inflammation.

The reason for the reduced CD14 production in MSU-induced inflammatory resolution is still unclear. It has been demonstrated that macrophages clear the cellular apoptotic remnants to help stop the inflammatory cascade through upregulating the anti-inflammatory cytokines, such as TGF-β and IL-10 [26]. Similarly, phagocytosis of crystals not only initiates the acute gout attack but also makes it possible to evolve into spontaneous resolution of acute gout attack by producing TGF-β and IL-10 [30]. These anti-inflammatory cytokines play an important role in inhibiting the inflammatory process, including inhibition of the receptor expression on the surface of leukocytes [26]. Furthermore, numerous research also demonstrated that the pathologic potential of MSU can be modulated by proteins and other agents, which might be the explanation for why crystals are not always inflammatory [31, 32]. Recently, neutrophil extracellular trap formation (NETosis) was also involved in the self-limited inflammation. It is highly potent to trap and clear MSU-induced inflammatory cytokines within minutes [27]. In this study, we found that CD14 was positively correlated with the inflammatory marker CRP. The glucocorticoid (GC) treatment was often used in controlling sepsis, which was associated with the downregulation of CD14 production in monocytes and macrophage [33]. Because MSU crystals taken by phagocytes were dependent on TLR4, TLR2, and CD14 [23–25], glucocorticoid was often used to restrain the inflammatory response induced by MSU [34]. Although CD14 was important for the development of gout, we observed a decreased CD14 production during the development of gout patients. It indicated that CD14 might contribute to spontaneous rapid resolution of inflammation.

Previous study showed that acute gouty inflammation is triggered by cellular recognition of the naked MSU crystal which was dependent on CD14 [25], and the detection of monocytes and macrophages having ingested MSU crystals is the gold standard clinical procedure to identify gout. However, the phagocytosis of crystals will promote naive macrophages to a mature type, which can produce lots of anti-inflammatory cytokine TGF-β. Consistently, noninflammatory deglutition of MSU crystals was observed in the mature macrophages and macrophage cell lines in vitro.
Therefore, blockage of MSU ingestion by downregulating CD14 expression might be a potential therapy for acute gout attack. Furthermore, some studies also showed that the self-limitation of gout can be induced by phagocytosis of crystals by macrophages, leading to the suppression of cellular inflammatory signaling pathway activation. Our study here demonstrated that both mCD14 and sCD14 expressions were decreased in gout patients when compared with healthy control subjects. Interestingly, mCD14 can be cleaved into sCD14 form, which can be served as a macrophage activity marker. The serum sCD14 levels were increased in patients with multiple sclerosis [36], and sCD14 is thought to be an early diagnostic and prognostic marker for patients with systemic infections [37]. However, sCD14 was decreased in MSU-induced inflammation in our study. These data provide a novelty mechanism in the regulation of CD14 expression, and further study should be conducted to certify the mechanism of decreased CD14 production in the development of gout.

In conclusion, these results suggested that CD14 might play a vital role in the mechanism of spontaneous remission of gout. The understanding of the detailed mechanism will provide us a novel opportunity to interfere with inflammation induced by MSU. Certainly, further studies are required to explore the specific regulation mechanism between CD14 and gout.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

LD, JL, YLW, and JC conceived and designed this study and were responsible for the integrity of the work, interpretation of data, and drafting of the manuscript. YYW, YLW, YL, and JC gave final approval to the version of the paper to be published. QF, KS, LD, and JL participated in clinical material collection, cell culture, and ELISA test. All authors reviewed and approved the submission. Lihua Duan and Jiao Luo have contributed equally to this work.

Acknowledgments

This research was supported by grants from the National Natural Science Foundation of China (NSFC 81671544 and 81871286 to Lihua Duan and 81860293 to Youlian Wang) and Outstanding Innovation Team, Frontier Science Key Research Project of Jiangxi Provincial People’s Hospital (19-008). We thank all the patients and volunteers who participated in this study.

References

[1] W. E. Cayley Jr., “Gout,” The BMJ, vol. 341, no. 2, article c6155, 2010.
[2] D. J. McCarty and J. L. Hollander, “Identification of urate crystals in gouty synovial fluid,” Annals of Internal Medicine, vol. 54, pp. 452–460, 1961.
[3] M. K. Kutting and B. L. Firestein, “Altered uric acid levels and disease states,” The Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 1, pp. 1–7, 2008.
[4] H. K. Choi, D. B. Mount, A. M. Reginato, American College of Physicians, and American Physiological Society, “Pathogenesis of gout,” Annals of Internal Medicine, vol. 143, no. 7, pp. 499–516, 2005.
[5] B. N. Cronstein and P. Sunkureddi, “Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis,” Journal of Clinical Rheumatology, vol. 19, no. 1, pp. 19–29, 2013.
[6] N. Busso and H. K. Ea, “The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis),” Reumatismo, vol. 63, no. 4, pp. 230–237, 2012.
[7] J. D. Bieber and R. A. Terkeltaub, “Gout: on the brink of novel therapeutic options for an ancient disease,” Arthritis and Rheumatism, vol. 50, no. 8, pp. 2400–2414, 2004.
[8] H. K. Ea, “Mechanisms of gout inflammation,” La Presse Médicale, vol. 40, no. 9, pp. 836–843, 2011.
[9] S. L. Wallace, H. Robinson, A. T. Masi, J. L. Decker, D. J. McCarty, and T. F. Yü, “Preliminary criteria for the classification of the acute arthritis of primary gout,” Arthritis and Rheumatism, vol. 20, no. 3, pp. 895–900, 1977.
[10] P. S. Tobias and R. J. Ulevitch, “Lipopolysaccharide binding protein and CD14 in LPS dependent macrophage activation,” Immunobiology, vol. 187, no. 3-5, pp. 227–232, 1993.
[11] M. O. Labeta, R. Landmann, J. P. Obrecht, and R. Obst, “Human B cells express membrane-bound and soluble forms of the CD14 myeloid antigen,” Molecular Immunology, vol. 28, no. 1-2, pp. 115–122, 1991.
[12] V. Verhasselt, C. Buelens, F. Willems, D. De Groote, N. Haeflner-Cavaillon, and M. Goldman, “Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway,” The Journal of Immunology, vol. 158, no. 6, pp. 2919–2925, 1997.
[13] S. D. Wright, R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison, “CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein,” Science, vol. 249, no. 4975, pp. 1431–1433, 1990.
[14] V. Bazil and J. L. Strominger, “Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes,” The Journal of Immunology, vol. 147, no. 5, pp. 1567–1574, 1991.
[15] J.-J. Durieux, N. Vita, O. Popescu et al., “The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes,” European Journal of Immunology, vol. 24, no. 9, pp. 2006–2012, 1994.
[16] C. J. Thomas, M. Kapoor, S. Sharma et al., “Evidence of a trimolecular complex involving LPS, LPS binding protein and soluble CD14 as an effector of LPS response,” FEBS Letters, vol. 531, no. 2, pp. 184–188, 2002.
[17] M. Triantaflilou and K. Triantaflilou, “Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster,” Trends in Immunology, vol. 23, no. 6, pp. 301–304, 2002.

[18] R. Landmann, C. Ludwig, R. Obrits, and J. P. Obrecht, “Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages,” Journal of Cellular Biochemistry, vol. 47, no. 4, pp. 317–329, 1991.

[19] H. W. L. Ziegler-Heitbrock and R. J. Ulevitch, “CD14: cell surface receptor and differentiation marker,” Immunology Today, vol. 14, no. 3, pp. 121–125, 1993.

[20] P. Buflfi, G. Stiegler, M. Schuchmann et al., “Soluble lipopolysaccharide receptor (CD14) is released via two different mechanisms from human monocytes and CD14 transfec-tants,” European Journal of Immunology, vol. 25, no. 2, pp. 604–610, 1995.

[21] C. J. Kirschning, H. Wesche, T. Merrill Ayres, and M. Rothe, “Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide,” The Journal of Experimental Medicine, vol. 188, no. 11, pp. 2091–2097, 1998.

[22] S. Bas, B. R. Gauthier, U. Spenato, S. Stingelin, and C. Gabay, “CD14 is an acute-phase protein,” The Journal of Immunology, vol. 172, no. 7, pp. 4470–4479, 2004.

[23] R. Liu-Bryan, K. Pritzker, G. S. Firestein, and R. Terkeltaub, “TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation,” The Journal of Immunology, vol. 174, no. 8, pp. 5016–5023, 2005.

[24] R. Liu-Bryan, P. Scott, A. Sydlaske, D. M. Rose, and R. Terkeltaub, “Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation,” Arthritis & Rheumatism, vol. 52, no. 9, pp. 2936–2946, 2005.

[25] P. Scott, H. Ma, S. Viriyakosol, R. Terkeltaub, and R. Liu-Bryan, “Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals,” The Journal of Immunology, vol. 177, no. 9, pp. 6370–6378, 2006.

[26] S. Steiger and J. L. Harper, “Mechanisms of spontaneous resolution of acute gouty inflammation,” Current Rheumatology Reports, vol. 16, no. 1, p. 392, 2014.

[27] G. Schett, C. Schauer, M. Hoffmann, and M. Herrmann, “Why does the gout attack stop? A roadmap for the immune pathogenesis of gout,” RMD Open, vol. 1, article e000046, Supplement 1, 2015.

[28] T. Neogi, T. L. T. A. Jansen, N. Dalbeth et al., “2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 74, no. 10, pp. 1789–1798, 2015.

[29] C. N. Serhan and J. Savill, “Resolution of inflammation: the beginning programs the end,” Nature Immunology, vol. 6, no. 12, pp. 1191–1197, 2005.

[30] Y. H. Chen, S. C. Hsieh, W. Y. Chen et al., “Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1655–1663, 2011.

[31] A. K. So and F. Martinon, “Inflammation in gout: mechanisms and therapeutic targets,” Nature Reviews Rheumatology, vol. 13, no. 11, pp. 639–647, 2017.